Pfizer pulls trigger on Voyager gene therapy capsid deal, clearing it to fire TRACER at CNS disease

Pfizer pulls trigger on Voyager gene therapy capsid deal, clearing it to fire TRACER at CNS disease

Source: 
Fierce Biotech
snippet: 

Pfizer has delivered a split decision on Voyager Therapeutics’ capsids. After spending one year assessing the capsids, the Big Pharma has paid $10 million to take up its option to use the gene therapy technology against a rare neurological disease target but backed out of the cardiovascular part of the deal.